Positive results of the bioequivalence study of Kimozo®
May 31, 2022 · The study objective was to evaluate primarily the bioequivalence between KIMOZO® oral suspension and TEMODAL® capsules, to define KIMOZO® pharmacokinetic …
ORPHELIA Pharma Selects Tanner Pharma Group to Initiate …
KIMOZO ® 40 mg/ml is a liquid, taste-masked and ready-to-use drinkable formulation of temozolomide developed in collaboration between the pharmacists and clinicians of Gustave …
Inclusion of the first patient in a clinical study evaluating Kimozo ...
Oct 5, 2020 · Kimozo (also known as ORP-005 or Ped-TMZ) is a ready-to-use and taste-masked oral suspension of temozolomide that is currently under development to address children …
European Patent covering Kimozo® - ORPHELIA Pharma
Jun 16, 2021 · Kimozo® (also known as ORP-005 or Ped-TMZ) is a ready-to-use and taste-masked oral suspension of temozolomide that is currently under development to address the …
Temozolomide Oral Suspension in Pediatric Cancer - ICH GCP
Oct 20, 2020 · The TEMOkids study is an international open-label, non-randomized, prospective, single-arm phase 1 study to determine the pharmacokinetic (PK) parameters of a single dose …
ORPHELIA Pharma and Gustave Roussy announce issuance of …
Jun 16, 2021 · Kimozo® results from the collaboration between the pharmacists and clinicians from Gustave Roussy and ORPHELIA Pharma. “Temozolomide is an essential oncology drug …
Kimozo (temozolomide oral suspension) / Orphelia Pharma
(ASCO 2022) - P1 | "The oral suspension of temozolomide (Kimozo) and capsule of temozolomide (Temodal) are bioequivalent under fasting conditions in patients with CNS …
ORPHELIA Pharma chooses Tanner Pharma to distribute Kimozo
Apr 19, 2023 · Kimozo 40mg/ml is a liquid, taste-masked and ready-to-use drinkable formulation of an anti-cancer drug, temozolomide, approved for use in Europe as capsules or as an IV …
KIMOZO® 40 mg/ml is a ready-to-use and taste-masked oral suspension of temozolomide to be used for the treatment of pediatric patients aged 1 to 6 years and in patients older than 6 years …
ORPHELIA Pharma and Gustave Roussy announce the publication …
Jun 9, 2022 · KIMOZO® 40 mg/ml is a liquid, taste-masked and ready-to-use oral formulation of temozolomide developed in collaboration between the pharmacists and clinicians of Gustave …